AnaptysBio Inc. (NASDAQ:ANAB) stock is down -1.34% to close at $16.99 on Thursday, 12/26/19. ANAB stock is lower by -$0.23 from the previous closing price of $17.22 on volume of 427183 shares. In the meantime, ANAB was trading in the Healthcare sector, the stock is trading -79.55% low as compared to its 52-week high price and 69.90% high as compared to its 52-week low price. Of example, both the price and the high and low measurements of 52 weeks will give you a clear image for determining the price track. The firm has a Weighted Alpha of -14.2. A positive weighted alpha shows that over the past year the stock has risen. A negative means that over the same period the stock is down.What do the Analysts Think?
Over the last 12 months, AnaptysBio Inc. (ANAB) stock has fallen by -72.40 percent, and Wall Street analysts’ average rating is a Hold. ANAB stock has an average target price of $18.29 in addition to the average rating from Wall Street analysts. This suggests investors foresee the inventory in the next 12 months to benefit 54.22%.
Estimates of future earnings are probably the most important feedback when attempting to evaluate a company. Analysts can then use cash flow analysis to approximate fair value for a company by placing estimates on a company’s earnings for certain periods. In case of AnaptysBio Inc. (ANAB), the Consensus Average Estimate of EPS for fiscal year 12/2019 according to 6 analysts is at -$3.98 per share. The high EPS estimate is -$3.22 per share and the low estimate is -$4.56 per share. The Average estimate indicates the -59.20% growth as compared to the prior year estimated EPS of -$2.50 per share.
AnaptysBio Inc. also currently has an EPS Growth of -64.40 percent for current year, showing analysts have bearish about their potential for near-term earnings. EPS growth was -53.90 percent over the past five years, along with sales growth of -1.80 percent over the past five years. Next year’s EPS growth is estimated at 0.20%.
The performance of the stocks typically measures, how much a stock gain or lose its value during different time spans. AnaptysBio Inc. (NASDAQ:ANAB) has achieved around 31.10% in the last 30 days and around -52.75% over the last three months. The stock recorded return of 3.00% over a week. In the last 6 months, the stock has been observed at -68.84% return.Tracking the Profitability and Valuation Ratios
As of the last trading session the stock has achieved a market cap of $476.06M. Market capitalization is the cumulative dollar value of all of a company’s outstanding shares and is used to quantify businesses and consider their overall market value. The stock has attained Price-to-sales ratio of 95.21 replicates the cost to be found on sales by the market. The firm maintained Price-to-book ratio of 1.09, which is used to equate the market value of a stock with its book value.
Londei Marco, Chief Medical Officer of AnaptysBio Inc. (ANAB) exercised an option 46,202 shares of firm against total value of $320,180 at the rate of $6.93 on Nov 27. Suria Hamza, President, CEO of AnaptysBio Inc. (ANAB) exercised an option 10,000 shares of firm against total value of $11,200 at the rate of $1.12 on Nov 22. Suria Hamza, President, CEO of AnaptysBio Inc. sold 22,428 shares of firm against total value of $1,654,350 at the rate of $73.76 on Jun 10. Mostly, the investors and traders are looking for stocks with the high ownership of company’s management because they think that when the company’s management is the major shareholder of a firm, the management will run the business for itself and they will never act those activities which are against their interests and they will always try to create shareholder value in the long-term. Currently, 0.40% of AnaptysBio Inc.‘s shares possessed by insiders.